TY - JOUR
T1 - Prevention of infection of influenza virus in DQ6 mice, a human model, by a peptide vaccine prepared according to the cassette theory
AU - Matsuki, Naoto
AU - Ogasawara, Kazumasa
AU - Takami, Kimitaka
AU - Namba, Kenichi
AU - Takahashi, Akio
AU - Fukui, Yoshinori
AU - Sasazuki, Takehiko
AU - Iwabuchi, Kazuya
AU - Good, Robert A.
AU - Onoé, Kazunori
N1 - Funding Information:
We thank Dr. D. Mathis and Dr. C.H. Benoist for providing MHC class II KO mouse, Dr. Kida for providing influenza virus and helpful discussion. We thank also Ms. Yukie Yamaguchi for her secretarial assistance. This study was supported in part by Grant-in-Aid for Scientific Research by the Ministry of Health and Welfare, and The Ministry of Education, Science, Sports and Culture, Japan, and The Sagawa Cancer Foundation and The Hosinkai Mimura Hospital Foundation.
PY - 1999/3/5
Y1 - 1999/3/5
N2 - We proposed a strategy (cassette theory) in which non-binding peptides for murine major histocompatibility complex (MHC) class II molecules are introduced into a MHC-binding component to render the resultant hybrid peptides bound to the MHC and thus immunogenic in animals carrying the relevant MHC. It was shown that 46F/HA127-133/54A(18mer) peptide which was prepared by introducing hemagglutinin (HA)127-133 of influenza virus into the H-2Ab binding component induced significant T cell responses and antibodies (Ab) specific for HA127-133 in H-2Ab mice. Further we found that the H-2Ab binding component had a supermotif for human class II molecules (i.e. HLA- DQ6). In the present study, a new peptide vaccine, H3-H3, was prepared by combining 46F/HA127-133/54A(18mer) as a carrier and HA127-133 attached to the C terminus of 46F/HA127-133/54A(18mer) as a hapten and the effect of vaccine was examined in DQ6 mice which carry HLA-DQ6 alone as MHC class II molecules and thus may be regarded as a model of the DQ6 positive individuals. Since 46F/HA127-133/54A(18mer) induced merely Ab against HA127-133, it was assumed that H3-H3 induced mainly HA127-133 specific Ab in DQ6 mice without undesirable Ab production against the carrier. Indeed, H3-H3 elicited T cell responses and induced HA127-133 specific Ab in DQ6 mice. Furthermore, administration of H3-H3 inhibited growth of influenza virus until 9 weeks after the last immunization in DQ6 mice.
AB - We proposed a strategy (cassette theory) in which non-binding peptides for murine major histocompatibility complex (MHC) class II molecules are introduced into a MHC-binding component to render the resultant hybrid peptides bound to the MHC and thus immunogenic in animals carrying the relevant MHC. It was shown that 46F/HA127-133/54A(18mer) peptide which was prepared by introducing hemagglutinin (HA)127-133 of influenza virus into the H-2Ab binding component induced significant T cell responses and antibodies (Ab) specific for HA127-133 in H-2Ab mice. Further we found that the H-2Ab binding component had a supermotif for human class II molecules (i.e. HLA- DQ6). In the present study, a new peptide vaccine, H3-H3, was prepared by combining 46F/HA127-133/54A(18mer) as a carrier and HA127-133 attached to the C terminus of 46F/HA127-133/54A(18mer) as a hapten and the effect of vaccine was examined in DQ6 mice which carry HLA-DQ6 alone as MHC class II molecules and thus may be regarded as a model of the DQ6 positive individuals. Since 46F/HA127-133/54A(18mer) induced merely Ab against HA127-133, it was assumed that H3-H3 induced mainly HA127-133 specific Ab in DQ6 mice without undesirable Ab production against the carrier. Indeed, H3-H3 elicited T cell responses and induced HA127-133 specific Ab in DQ6 mice. Furthermore, administration of H3-H3 inhibited growth of influenza virus until 9 weeks after the last immunization in DQ6 mice.
UR - http://www.scopus.com/inward/record.url?scp=0033525772&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033525772&partnerID=8YFLogxK
U2 - 10.1016/S0264-410X(98)00336-3
DO - 10.1016/S0264-410X(98)00336-3
M3 - Article
C2 - 10195628
AN - SCOPUS:0033525772
SN - 0264-410X
VL - 17
SP - 1161
EP - 1168
JO - Vaccine
JF - Vaccine
IS - 9-10
ER -